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non-typeable plasmid, next to blaCMY-2 on an 80 kb IncK plasmid
and blaCTX-M-1 on a 100 kb IncI1 plasmid. The IncI1 plasmid was
further typed by plasmid multilocus sequence typing (pMLST) as
sequence type (ST) 7.
4 The coexistence of qnrS1 and blaSHV-12
has been reported on IncN plasmids in Klebsiella isolates from
Italy.
5 Nevertheless, to our knowledge, we describe the ﬁrst E.
coli isolate harbouring qnrS1 and blaSHV-12 on a single non-typeable
45 kb plasmid. The presence of blaCMY-2 on an IncK plasmid and
blaCTX-M-1 on an IncI1 plasmid was previously identiﬁed in E. coli
isolates from Dutch broiler chickens.
2 Moreover, IncI1 plasmids of
ST7 harbouring blaCTX-M-1 are frequently detected amongst ESBL-
producing E. coli from Dutch broiler chickens (pMLST databases:
http://pubmlst.org/plasmid/). Yet, we report the ﬁrst coexistence
of blaCTX-M-1, blaSHV-12 and blaCMY-2 genes next to qnrS1 in an
E. coli isolated from animals. In the E. coli isolate from a veal
calf (no. 77.01), qnrS1 was located on an IncX2 plasmid, which
has recently been described in E. coli from healthy animals in
Nigeria.
6 In the E. coli isolate from a broiler chicken (no. 74.21),
qnrB19 was also identiﬁed on an InX2 plasmid. The presence of
qnrB19 has been reported in E. coli isolated from animals on
ColE,
6 IncN
7 and IncR
8 plasmids, but not on IncX2.
Our results demonstrate the presence of qnr genes on two
different types of plasmids in E. coli isolated from animals. These
ﬁndings indicate the emergence of PMQR genes in the commensal
ﬂora of food-producing animals in the Netherlands. The remark-
able ﬁnding of the coexistence of three different cephalosporinase
genes on three different plasmids in a single E. coli isolate demon-
strates the complexity of the plasmid-mediated dissemination of
b-lactamase and PMQR genes in Enterobacteriaceae.
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Sir,
AntimicrobialresistanceincommonGram-negativeorganismssuch
as Escherichia coli isa major threat toglobal health,andparticularly
relevant to clinical management in resource-poor settings, where
access to appropriate antibiotics may be limited by cost. An
example of this is the Lao Peoples’ Democratic Republic (Laos),
which has some of the poorest health indicators in the south-east
Asia region,
1 and borders several countries reporting high rates of
CTX-M-mediated extended-spectrum b-lactamase (ESBL) and mul-
tidrugresistanceinE.coli.
2Weused acombination ofgenotypicand
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240phenotypic testingtocharacterize ESBL-producing E. coli isolated at
the Mahosot Hospital in Vientiane, April 2004–09.
Bloodstream E. coli isolates at the Mahosot Hospital have been
routinely tested for ESBL production since 2000; urine and pus iso-
lates have been tested since 2006. Speciation of isolates was done
using the API-20E or mini-API (bioMe ´rieux, France). Screening and
conﬁrmatory testing of isolates for ESBL production and additional
antibiotic susceptibility testing for the study were carried out in
accordance with published guidelines (CLSI and BSAC method-
ologies). Additional antibiotics tested included ciproﬂoxacin, genta-
micin, trimethoprim, nitrofurantoin, meropenem and amikacin.
DNA was prepared from boiled cell suspensions and subjected to
PCR analysis for blaCTX-M.
3 The resulting 504 bp amplicon (of the
876 bp blaCTX-M gene) was sequenced and genetic homologues
identiﬁed by querying the National Centre for Biotechnology Infor-
mation (NCBI) nucleotide database. Multilocus sequence typing of
E. coli was carried out in accordance with an established scheme
(http://mlst.ucc.ie/). Statistical analyses were undertaken with
Stata/SE11.1software.EthicalapprovalwasgrantedbytheNational
Ethical Committee for Health Research, Government of the Lao PDR
(Laos) and the Oxford Tropical Research Ethics Committee (UK).
Fifty-four ESBL-producing E. coli were identiﬁed during the
study period from blood (n¼18/197; 9%), urine (n¼23/354;
6%) and pus (n¼11/76; 14%) samples culturing E. coli, consist-
ent with the general epidemiology of extra-intestinal pathogenic
E. coli (ExPEC) infections. For two samples the source was not
conﬁrmed. All ESBL-producing E. coli isolates harboured
blaCTX-M, the invariable presence of which is similar to other mol-
ecular epidemiological studies carried out in Asia.
4 There was an
increase in the proportion of all microbiological specimens cultur-
ing E. coli during the study period (2.9% to 4.5%; Fisher’s exact
test, P¼0.02), and the proportion of ESBL-producing E. coli
more than tripled since their ﬁrst isolation in 2004 (3.9% to
13.3%; Fisher’s exact test, P¼0.04). While a survey in only one
hospital represents a singular snapshot of the overall epidemiol-
ogy, this study suggests the expansion of CTX-M ESBLs in E. coli in
Vientiane occurred relatively late, given that the CTX-M gene was
ﬁrst identiﬁed in 1991 and high rates of ESBL-producing E. coli
were reported in Asia as early as 1998–2002.
Considerable multidrug resistance was found amongst ESBL-
producing E. coli isolates, with 66% displaying resistance to a
further three classes of antibiotic (ciproﬂoxacin, trimethoprim
and gentamicin). The rate of ciproﬂoxacin resistance (91%)
was substantially higher than that in the 2008 Study for
Monitoring Antimicrobial Resistance Trends (SMART) survey of
ESBL-producing Enterobacteriaceae isolates in the Asia-Paciﬁc
region (64%),
2 and showed no association with year of isolation,
with ciproﬂoxacin resistance being the norm in ESBL-producing
E. coli in Laos since 2004. No carbapenem resistance was
found in this survey; only one isolate was resistant to amikacin.
CTX-M-14-like enzymes were most common [including
CTX-M-14/18, -17, -21, -24, -46, -47, -48, -49, -50, -83 and
-104; n¼22 (41%)], with CTX-M-15-like [including CTX-M-28,
-82 and -88; n¼15 (28%)], CTX-M-27 [n¼12 (22%)] and
CTX-M-55-like [including CTX-M-57, -69 and -79; n¼5 (9%)] var-
iants being identiﬁed in descending order of frequency. This
mimics to some degree the distribution seen in Thailand and
China, where the appearance of ESBLs in E. coli pre-dates that
seen in this study in Laos, suggesting plausible transmission net-
works between these countries sharing land borders.
Fifteen different sequence types (STs) were identiﬁed among
the ESBL-producing E. coli isolates (Table 1). While a pandemic
global lineage, ST-131, was the most frequently identiﬁed ST
(n¼17/54; 31%), of particular interest was the ﬁnding that
ST-648 was the second most common (n¼10/54; 19%). ESBL-
producing ST-648 has been identiﬁed to date in only a handful
of human clinical isolates, wild birds and poultry,
5 suggesting
the potential for zoonotic transmission. Poultry farming is
common in Laos, with 95% being of the ‘backyard’, small-
holding variety.
6 A further bird-associated strain (ST-1340),
which has not been found in human clinical samples before,
was also found in this study. ST-648 was signiﬁcantly associated
with CTX-M-15-like enzymes (Fisher’s exact test, P,0.0001).
This study describes the emergence and expansion since
2004 of ESBL-producing E. coli in Vientiane, Laos, and the invari-
able presence of the CTX-M gene. Local surveillance has the
capacity to demonstrate discrete features of ESBL-producing
E. coli molecular epidemiology. The diverse range of host bac-
terial genotypes and CTX-M variants identiﬁed in this study
support the notion that higher-resolution approaches, such as
those afforded by whole genome sequencing technology, are
required to gain a thorough understanding of the epidemiology
of this resistance problem.
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Table 1. Number of ESBL-producing E. coli isolates by ST per year; annual
periods run from 1 April of one year to 31 March of the following year
ST 2004–05 2005–06 2006–07 2007–08 2008–09 Total
12 1 1
38 1 1 2
69 2 2
88 1 1
95 1 1
101 1 1
131 1 4 4 8 17
167 2 2 4
209 1 1
354 1 3 1 5
405 1 1 2 4
410 3 3
648 1 2 7 10
744 1 1
1340 1 1
Total 2 4 6 16 26 54
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Sir,
The production of carbapenem-hydrolysing b-lactamases is
increasingly reported in Enterobacteriaceae. Among the different
types of carbapenemases, the emergence of the Ambler class A
KPC-type b-lactamases is of great concern, since those enzymes
hydrolyse all b-lactams with the exception of cephamycins.
Enterobacterial isolates producing KPC-type b-lactamases were
reported in many areas in the USA and subsequently worldwide.
1
The rapid dissemination of KPC enzymes among different entero-
bacterial species is related to the localization of blaKPC genes on
transferable broad host range plasmids and their association
with a transposon.
1 This dissemination has also been linked
with a ‘successful’ international clone of KPC-producing Klebsiella
pneumoniae of sequence type (ST) 258.
2
Earlyin2011,amiddle-agedpatientwastransferredfromahos-
pital in Mumbai, India, to the hospital of Dinan, France. The patient
suffered from pleurisy due to Streptococcus pneumoniae for which
hehadreceivedacombinationofimipenem,vancomycinandpiper-
acillin/tazobactam in India. Upon admission,a rectalswabrevealed
the presence of a multidrug-resistant Escherichia coli (designated
strainGRU)withreducedsusceptibilitytocarbapenems.Nosecond-
ary local transmission occurred at the Dinan hospital following the
r a p i di m p l e m e n t a t i o no fs t r i c ti n f e c t i o nc o n t r o lm e a s u r e s .
The antibiogram determined by the disc diffusion method and
MICs determined by Etest (AB bioMe ´rieux, Solna, Sweden) and
interpreted according to the CLSI guidelines
3 revealed that
E. coli strain GRU was resistant to all penicillins and expanded-
spectrum cephalosporins, to ertapenem (MIC .32 mg/L) and
to meropenem (MIC 8 mg/L) and was of intermediate suscepti-
bility to imipenem (MIC 1.5 mg/L). The isolate was susceptible
to tetracycline and fosfomycin, and MICs of tigecycline and colis-
tin were 1 and 0.5 mg/L, respectively. However, it was resistant
at a high level to all ﬂuoroquinolones (MICs .256 mg/L). Molecu-
lar investigations performed as described previously
1 identiﬁed
the blaKPC-2 gene. Isolate GRU also harboured the blaTEM-1 and
blaOXA-1 genes. Plasmid location of the blaKPC-2 gene was con-
ﬁrmed by electroporation of a plasmid DNA preparation obtained
by the Kieser method into E. coli TOP10 with selection on Trypti-
case soy plates containing ampicillin (100 mg/L).
1 Molecular and
phenotypic analysis of the E. coli transformant conﬁrmed that
blaKPC-2 was located on an  20 kb plasmid. The blaKPC-2-positive
plasmid was non-typeable using PCR-based replicon typing.
4 No
other antibiotic resistance marker was co-transferred. PCR
mapping performed as described
1 showed that the blaKPC-2
gene was part of the Tn4401 transposon. It is noteworthy that
E. coli GRU additionally harboured a gene encoding the 16S
rRNA methylase ArmA, conferring high-level resistance to all
aminoglycosides (MICs of gentamicin, netilmicin, kanamycin
and tobramycin .256 mg/L). Interestingly, KPC-2- and ArmA-
producing Enterobacter cloacae and K. pneumoniae isolates
have been reported in China and Poland.
5,6 Multilocus sequence
typing (MLST) performed according to the protocol described
on the E. coli MLST web site (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/EColi.html) showed that E. coli GRU belonged
to ST101, recently reported to be the most frequent
NDM-1-producing E. coli clone in the UK and Pakistan.
7 That
study reported a KPC-producing E. coli originating from India. It
remains to be determined to what extent the spread of KPC-type
enzymes will contribute to the problem of carbapenem resistance
in India, which currently is commonly regarded as reﬂecting the
dissemination of the NDM-1 carbapenemase.
8
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